| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 54
| Issue : 1 | Page : 1-6 |
|
|
The hemodynamic and analgesic efficacy of subcutaneous dexmedetomidine versus Marcaine 0.5% in postoperative pain management following herniorrhaphy
Shirin Pazoki1, Hesameddin Modir2, Alireza Kamali1, Amirreza Naimi2, Mehdi Maktubian3, Nazanin Amini3
1 Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran
2 Department of Surgery, Arak University of Medical Sciences, Arak, Iran
3 Student Research Center, Arak University of Medical Sciences, Arak, Iran
Correspondence Address:
Hesameddin Modir
Departments of Surgery, Arak University of Medical Sciences, Arak
Iran
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/fjs.fjs_93_20
|
|
|
Background: This study addressed the comparative hemodynamic and analgesic effects of subcutaneous dexmedetomidine versus Marcaine 0.5% on herniorrhaphy scheduled patients, as well as postoperative pain management.
Materials and Methods: A double-blind trial was conducted in three groups of patients (n = 120) scheduled for herniorrhaphy. The study groups were (i) Marcaine + dexmedetomidine (MAR-DEX) group, receiving Marcaine 0.5% (5 mg) + dexmedetomidine (1 mcg/kg), (ii) MAR group, Marcaine 0.5% (5 mg), and (iii) PBO group, placebo, subcutaneously. Vital signs (blood pressure/heart rate/SaO2), as well as pain scores (using the Visual Analog Scale) at recovery and certain time points (1, 2, 4, 6, 12, and 24 h postoperatively) were measured. Moreover, the overall opioid administered postoperatively and the side effects were recorded. Data were analyzed by SPSS (version 20) software by analysis of variance and repeated measurement tests.
Results: Lower pain score was revealed in the MAR-DEX group and higher one in the PBO group (P < 0.001), whereas the lowest opioid use was observed in the MAR-DEX group (P < 0.001).
Conclusion: Adding dexmedetomidine had benefits of relieving pain and reducing opioid use without any side effects.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
